Cochrane Review Group

Eyes and Vision

171 systematic reviews in Eyes and Vision ask 2,112 questions. 27.8% have no studies to answer them, 21.1% rest on very low certainty evidence and 20.2% reach moderate or high certainty.

Reviews

171

Questions

2,112

current versions

No studies

27.8%

Moderate or high

20.2%

No studies 587 · 27.8%Ungraded 95 · 4.5%Very low 446 · 21.1%Low 557 · 26.4%Moderate 361 · 17.1%High 66 · 3.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Eyes and Vision

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
LipiFlow vs basic warm compresses Mean change from baseline in symptom scores at 1 to 4 weeks (lower is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane	no estimate extracted	NR	Very low
LipiFlow vs thermostatic devices Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane	no estimate extracted	4 studies · 445 participants	Very low
LipiFlow vs basic warm compresses Mean change from baseline in meibomian gland expression scores at 1 to 4 weeks (higher is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane	SMD 1.31	2 studies · 76 participants	Very low
LipiFlow vs basic warm compresses Mean change from baseline in meibum quality scores at 1 to 4 weeks (higher is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane	no estimate extracted	1 study · 46 participants	Very low
LipiFlow vs thermostatic devices Mean change from baseline in symptom scores at 1 to 4 weeks (lower is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane	no estimate extracted	NR	Very low
Face‐down positioning vs other positioning Proportion of eyes with retinal displacement at 6 months or later (RR < 1 favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	RR 0.73 [0.54, 0.99]	1 study · 239 participants	Very low
Face‐down positioning vs other positioning Mean change in logMAR or Snellen visual acuity from baseline to 3 months or later (lower is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	no estimate extracted	1 study · 56 participants	Very low
Face‐down positioning vs other positioning Mean objective distortion score at 3 months or later (lower is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	MD 1.8	1 study · 219 participants	Very low
Face‐down positioning vs other positioning Quality of life assessments at 3 months or later (higher is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	no estimate extracted	1 study · 217 participants	Very low
Face‐down positioning vs other positioning Frequency of intervention‐related ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	no estimate extracted	1 study · 262 participants	Very low
Face‐down positioning vs other positioning Frequency of intervention‐related non‐ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	no estimate extracted	NR	No studies
Lutein with or without zeaxanthin vs placebo Adverse effects · people with AMD Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration (2023) · Cochrane	OR 1.06	NR	Very low

Reviews 171

Single herbal medicine for diabetic retinopathy

Zhang, HW, Zhang, H, et al. · Cochrane Database of Systematic Reviews · 2018

Eyes and Vision

Thinnest evidence

Reviews 171

Single herbal medicine for diabetic retinopathy

Cyclodestructive procedures for non‐refractory glaucoma

Monotherapy laser photocoagulation for diabetic macular oedema

Interventions for eye movement disorders due to acquired brain injury

Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema

Blue‐light filtering intraocular lenses (IOLs) for protecting macular health

Interventions to increase attendance for diabetic retinopathy screening

Descemet's membrane endothelial keratoplasty (DMEK) versus Descemet's stripping automated endothelial keratoplasty (DSAEK) for corneal endothelial failure

Different lasers and techniques for proliferative diabetic retinopathy

Antioxidant vitamin and mineral supplements for preventing age‐related macular degeneration

Aqueous shunts for glaucoma

Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery

Neuroprotection for treatment of glaucoma in adults

Surgery for cataracts in people with age‐related macular degeneration

Punctal occlusion for dry eye syndrome

Endonasal versus external dacryocystorhinostomy for nasolacrimal duct obstruction

Autologous serum eye drops for dry eye

Topical non‐steroidal anti‐inflammatory drugs for analgesia in traumatic corneal abrasions

Different‐sized incisions for phacoemulsification in age‐related cataract

Non‐steroidal anti‐inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery

Topical medication instillation techniques for glaucoma

Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty

Acupuncture for acute hordeolum

Laser‐assisted subepithelial keratectomy (LASEK) versus laser‐assisted in‐situ keratomileusis (LASIK) for correcting myopia

Probing for congenital nasolacrimal duct obstruction